Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Cadrenal Therapeutics, Inc. Common Stock Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock

CVKD
Rangering i aksjer #33959
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise... Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Aksjekurs
$1.83
Sist synkronisert: 2026-08-14
Markedsverdi
$6.53M
Endring (1 dag)
-1.61%
Endring (1 år)
-85.57%
Land
US
Handel Cadrenal Therapeutics, Inc. Common Stock (CVKD)

Kategori

Healthcare
Inntekter for Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Cadrenal Therapeutics, Inc. Common Stock er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Cadrenal Therapeutics, Inc. Common Stock fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE